A study following more than half a million adults has turned up an unexpected signal in human breath: people with higher levels of exhaled carbon monoxide were less likely to go on to develop Parkinson's disease. The findings, published in JAMA Neurology, may help explain one of neurology's most stubborn puzzles — why smokers consistently develop the neurodegenerative condition less often than nonsmokers — and they open the door to a possible new treatment pathway.
The work was led by researchers from Oxford Population Health together with collaborators at Peking University, and it draws on one of the largest long-running health datasets available for this kind of question. Rather than starting from smoking behavior alone, the team looked at a measurable byproduct of smoke exposure that the human body also makes on its own.
Why Parkinson's research keeps circling back to smoking
Parkinson's disease is the second most common neurodegenerative condition in the world. It affects more than 10 million adults globally, and its prevalence is climbing, driven in part by an aging population. That trajectory has made the search for modifiable risk factors urgent, and few leads have been as persistent — or as awkward — as cigarette smoking.
Decades of observation have repeatedly shown that smokers appear to develop Parkinson's less often than people who never smoke. The pattern is robust enough that it has resisted being written off as an artifact, yet no study had settled the obvious follow-up question: which component of tobacco smoke, if any, is responsible? Nicotine has long been the leading suspect, but the evidence has never been strong enough to close the case. The Oxford and Peking University team took a different route, asking whether a gas long dismissed as pure poison might be the missing piece.
Carbon monoxide's double life in the body
Carbon monoxide is best known as a lethal hazard. At high concentrations it displaces oxygen in the blood and can kill within minutes, which is why the gas is treated as a serious public health threat rather than a therapeutic candidate. But the molecule has a second, quieter identity.
The human body naturally produces small quantities of carbon monoxide, and at those low levels it appears to perform useful housekeeping work. According to the study's framing, endogenously produced CO helps prevent cell damage, dampens inflammation and supports immune responses. That biology has intrigued researchers for years.
Laboratory and animal experiments have previously hinted that low-dose carbon monoxide might protect brain health, but human evidence has been thin. What was missing was a study that measured exhaled CO directly in a large population and then watched who developed Parkinson's disease over time. Until now, no study had done both.
How the study was built
To bridge that gap, the researchers turned to the China Kadoorie Biobank, a large prospective resource that combines detailed lifestyle information with biological measurements. The design rested on several components:
- Detailed smoking histories for roughly half a million adult participants, capturing who smoked, how much and for how long.
- Exhaled breath measurements of carbon monoxide, which serve as a marker of recent CO exposure — including exposure generated by smoking.
- Longitudinal disease tracking using death registries and health insurance records, allowing the team to identify which participants developed Parkinson's and other conditions.
- Twelve years of follow-up, a window long enough for a slowly progressive neurodegenerative disease to surface in a meaningful number of people.
That combination is what makes the analysis unusual. Rather than inferring exposure from questionnaires alone, the study had a direct physiological readout of carbon monoxide in each participant's breath, paired with years of prospective outcome data.
What the researchers found
Regular smokers in the cohort carried significantly higher levels of exhaled carbon monoxide than nonsmokers. They also showed roughly a 30% lower risk of developing Parkinson's disease over the follow-up period. The analysis then moved to the more revealing question: whether the association tracked with measured carbon monoxide levels rather than with smoking status alone — the distinction that would separate CO from the hundreds of other compounds in tobacco smoke.
The headline result is that higher exhaled carbon monoxide was associated with a lower risk of Parkinson's disease. In other words, a gas that clinicians normally measure in order to warn people about smoke exposure may also be a marker of something protective in the brain — or a clue pointing toward one.
What this does and does not mean
The findings should not be read as a case for taking up smoking. Cigarettes remain a leading cause of cancer, cardiovascular disease and respiratory illness, and the study does not suggest otherwise. Nothing in an observational cohort can establish that carbon monoxide itself causes the reduction in Parkinson's risk; the association could reflect other biology that happens to travel alongside CO levels.
- Association, not causation. The study links exhaled CO to lower Parkinson's risk; it does not prove that CO prevents the disease.
- Dose matters enormously. Carbon monoxide is toxic at high concentrations and remains a significant poisoning hazard.
- An observational design. Prospective cohorts can reveal patterns over time, but they cannot rule out every confounding factor.
- No clinical recommendation follows. There is currently no CO-based therapy approved for Parkinson's disease, and none should be improvised.
What the study does offer is a plausible biological thread connecting a well-documented epidemiological pattern to a measurable molecule — and a reason to investigate that molecule under controlled conditions rather than through cigarette smoke.
The path toward a possible treatment
If low-dose carbon monoxide genuinely protects neurons, the therapeutic challenge becomes delivery: how to administer a gas safely, at a precise dose, without the thousands of harmful compounds that accompany it in tobacco smoke. That is a question for controlled clinical research, not for consumers, and any such approach would need to clear the same rigorous safety and efficacy testing as any other drug candidate.
The value of this study lies in narrowing the field of suspects. For years, researchers chasing the smoking-Parkinson's paradox had little more than nicotine to work with. Measuring exhaled carbon monoxide in half a million adults gives them a second, testable hypothesis — one grounded in human data rather than animal models alone.
Key takeaways
- A study of more than 500,000 adults found that higher exhaled carbon monoxide levels were associated with a lower risk of Parkinson's disease.
- Regular smokers had higher exhaled CO and about a 30% lower risk of developing Parkinson's than nonsmokers.
- The body naturally produces small amounts of CO that help prevent cell damage, reduce inflammation and support immune responses.
- Earlier laboratory and animal work suggested low-dose CO could protect brain health, but human evidence had been lacking.
- The research, published in JAMA Neurology and led by Oxford Population Health with Peking University collaborators, points to a potential new treatment pathway — not a reason to smoke.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
